Validated model for prediction of recurrent hepatocellular carcinoma after liver transplantation in Asian population

Figure 1 Method of total risk score development. AFP: Alpha fetoprotein; HCC: Hepatocellular carcinoma; CI: Confidence interval.

Figure 2 ROC curve for scoring system in the training set. ROC: Receiver-operating characteristic.

Figure 3 Risk stratification model in the training set. AFP: Alpha fetoprotein; LT: Liver transplantation; HCC: Hepatocellular carcinoma.

Figure 4 Performance of risk stratification model in relation to recurrent hepatocellular carcinoma in the training set. ROC: Receiver-operating characteristic.

Figure 5 Risk stratification models with corresponding hepatocellular carcinoma recurrence rates in the training set. AFP: Alpha fetoprotein; ROC: Receiver-operating characteristic.

Figure 6 Comparison of the areas under ROC curve between the current scoring system, the alpha fetoprotein model, and the RETREAT score in the validation set. AFP: Alpha fetoprotein; LT: Liver transplantation; HCC: Hepatocellular carcinoma; ROC: Receiver-operating characteristic; RETREAT: Risk estimation of tumor recurrence after transplant.

Figure 7 Risk stratification model with corresponding hepatocellular carcinoma recurrence rates in the validation set. ROC: Receiver-operating characteristic.

Figure 8 Diagram showing discrepancy between the expected and observed hepatocellular carcinoma recurrence rates.

Figure 9 Disease-free survival of patients in different risk strata. DFS: Disease-free survival.